Navigation Links
NxStage Medical Announces Needle Supply Agreement with DaVita
Date:1/7/2008

LAWRENCE, Mass., Jan. 7 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that it has signed a five-year agreement with DaVita, Inc. (NYSE: DVA) to continue to supply DaVita's dialysis centers with MasterGuard and ButtonHole safety needle sets, subject to certain terms and conditions. Safety needles are essential products used to access patients' blood during the vast majority of chronic dialysis therapy treatments. MasterGuard is the leading product in this market, and became part of NxStage's product portfolio through the recent acquisition of Medisystems.

DaVita and its predecessors have a long, successful history with Medisystems brand needles.

"We are very pleased to continue our long-standing relationship as DaVita's primary needle supplier," said Jeffrey H. Burbank, President & CEO of NxStage Medical. "Medisystems' high quality, innovative products was one of the key reasons we acquired the company last year. This new agreement with DaVita solidifies NxStage's position as a dialysis industry leader in-center, as well as in the critical care and home hemodialysis markets."

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawr
'/>"/>

SOURCE NxStage Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. NxStage Medical to Present at the Piper Jaffray Healthcare Conference on November 27, 2007
2. Arbios Announces SEPET(TM) Manufacturing Agreement With NxStage Medical
3. NxStage(R) Medical to Report Third Quarter 2007 Financial Results on Friday, November 2nd
4. NxStage Medical Provides Update on Medisystems Acquisition
5. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
6. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
7. Triage study challenges notions of emergency medical response to disaster
8. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
9. Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics
10. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
11. Inverness Medical Innovations Acquires ParadigmHealth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... 30, 2015 , ... The maximum number of shares proposed to be purchased ... shares of unvested restricted stock). On June 29, 2015, the last trading day prior ... reported on the OTCBB was $2.29 per share. , The tender offer will expire ...
(Date:6/30/2015)... 30, 2015  The University of California, San ... and UC San Diego Extension announced their third ... Aug.  12 – 14, 2015, at UC San ... provides an intense exposure to best practices and ... well-suited to biologists, process engineers and business executives ...
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - RepliCel ... clinical stage regenerative medicine company focused on the ... first participant in its Phase 1/2 clinical trial ... chronic unilateral Achilles tendinosis, has been enrolled and ... intra-tendon ultrasound-guided injections. RCT-01 is comprised of non-bulbar ...
(Date:6/30/2015)... ... June 30, 2015 , ... Southern Illinois University ... position of vice president of instruction at Chippewa Valley Technical College (CVTC) and ... the opportunity to lead SIUE during the past three years,” Furst-Bowe said. “I ...
Breaking Biology Technology:Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3
... /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS), a ... of technologies targeting the chronic inflammation,underlying cardiovascular and ... CEO, will present a Company Overview at BIO,CEO ... York City, at 11:00,a.m. (ET) on Tuesday, February ...
... Feb. 5 EntreMed, Inc.,(Nasdaq: ENMD ) ... of cancer and inflammatory diseases, today,announced that James ... a Corporate overview at the BIO CEO and ... February 11-13, 2008. Mr. Burns,presentation is scheduled for ...
... to Advise on Development of New Drug ... Candidate to Treat Autoimmune Disease -, SAN ... development company, announced today that it,has appointed the first five ... protein licensed from Amgen in December 2007 for,the treatment of ...
Cached Biology Technology:Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel 2Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel 3EntreMed to Present at BIO CEO and Investor Conference 2Anthera Pharmaceuticals Forms Scientific Advisory Board 2
(Date:6/30/2015)... NEW YORK , June 30, 2015 To ... biometric security provider HYPR Corp. announced today the addition of ... will serve as board advisor and David Raviv ... to the team underscore HYPR Corp.,s commitment to providing the ... , Dimitri Sirota co-founded Layer 7 Technologies, a ...
(Date:6/30/2015)... 30, 2015 Genisphere announced ... to help further develop Genisphere,s therapeutics capabilities and portfolio. ... having spent much of the last 25 years in ... Bioscience, and Johnson & Johnson. Tom started his career ... Biotech Corporate Finance. He graduated from Dartmouth College with ...
(Date:6/29/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... America Biomedical Sensors market is estimated at $0.65 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... between researchers at the Hebrew university of Jerusalem and ... treatment of brain diseases. The researchers found that TyrNovo,s ... process of aging in order to protect the brain ... first and important step towards the development of future ...
... two-thirds (65%) of Americans say it,s likely there ... ahead as Congress continues to debate deficit and ... opinion poll commissioned by Research!America and the American ... party affiliations: Democrats (66%), Republicans (65%) and Independents ...
... and environmental organisations are working together to influence future ... English Channel is used daily by more than 500 ... shores in Southern England and Northern France, and it ... Now 12 organisations, led by Plymouth University, have ...
Cached Biology News:New compound for slowing the aging process can lead to novel treatments for brain diseases 2New compound for slowing the aging process can lead to novel treatments for brain diseases 3Majority of Americans believe another government shutdown likely in coming months 2Majority of Americans believe another government shutdown likely in coming months 3Anglo-French partnership develops guidance on future management of English Channel 2
... This antibody is specific for human cardiac troponin ... the Ca-binding signals responsible for contraction of cardiac ... troponin complex in human cells. It also cross-reacts ... Antigen: Highly purified human ...
... N-(2-Naphthoyl)-Val-phenylalaninal 2-Naphthoyl-VF-CHO White ... INERT GAS. A cell-permeable, reversible inhibitor of ... x-40 (ED 50 = 2.6 ... = 2.7 μM) in HEK293 cells ...
cystatin A (N-18)...
...
Biology Products: